Inside AstraZeneca’s abandoned UK vaccine plant deal as Labour and Tories face questions over £450m collapse
AstraZeneca’s planned vaccine hub for Liverpool is off the table - business editor Karl Matchett and Whitehall editor Kate ...
Personalized vaccine offers hope for patients with late-stage kidney cancer, clinical trial shows
Cancer researchers are one step closer to developing an effective vaccine to treat people with clear cell renal cell ...
The drug industry is having its own DeepSeek moment
It isn’t just artificial intelligence. Chinese biotech companies are now developing drugs faster and cheaper than their US ...
2 retirement shares that long-term investors should consider for steady income
Ken Hall takes a look at two big-name retirement shares in the FTSE 100 with market-leading positions and track records of solid dividend payouts.
HealthDay on MSN15h
Study Finds Exenatide Not Beneficial for Parkinson Disease
The glucagon-like peptide-1 receptor agonist exenatide does not yield improvement in measures of Parkinson disease seve ...
Hosted on MSN20h
Genentech eyes lupus market for Gazyva with positive Phase III data readout
Roche’s subsidiary Genentech has shared positive Phase III data with the US Food and Drug Administration (FDA) as the company ...
Hosted on MSN15h
Sanofi increases ownership stake partaking in pharma buyback trend
Just days after taking back some of the stake held by L’Oréal, Sanofi has agreed to repurchase its own shares worth €2bn ($2.08bn) from other stakeholders. The French drugmaker said it had entered a ...
pharmaphorum16h
AstraZeneca leads winners at Reuters Pharma Awards 2022
And the award goes to… The standout winner for Reuter's inaugural European Pharma awards was AstraZeneca (AZ), which took home two trophies. Kicking off the event with a bang, AZ scooped up the ...